These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. A preliminary investigation of the role of the phenylalanine:tyrosine ratio in children with early and continuously treated phenylketonuria: toward identification of "safe" levels. Sharman R; Sullivan K; Young R; McGill J Dev Neuropsychol; 2010; 35(1):57-65. PubMed ID: 20390592 [TBL] [Abstract][Full Text] [Related]
30. Improved identification of heterozygotes for phenylketonuria using blood neopterin and biopterin. Alós T; Bel Y; Cabello ML; Catalá JL; Dalmau J; Ferré J; García AM; Ruiz-Vázquez P J Inherit Metab Dis; 1993; 16(2):457-64. PubMed ID: 8412006 [TBL] [Abstract][Full Text] [Related]
31. Detection of phenylketonuria carriers. Kelly S; Rose F Public Health Rep (1896); 1969 Feb; 84(2):144-8. PubMed ID: 4980161 [No Abstract] [Full Text] [Related]
32. Serum prolactin as a biomarker for the study of intracerebral dopamine effect in adult patients with phenylketonuria: a cross-sectional monocentric study. Juhász E; Kiss E; Simonova E; Patócs A; Reismann P Eur J Med Res; 2016 May; 21(1):22. PubMed ID: 27169416 [TBL] [Abstract][Full Text] [Related]
33. The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria. Elsas LJ; Greto J; Wierenga A Mol Genet Metab; 2011 Apr; 102(4):407-12. PubMed ID: 21216643 [TBL] [Abstract][Full Text] [Related]
34. Effect of dietary aspartame on plasma concentrations of phenylalanine and tyrosine in normal and homozygous phenylketonuric patients. Mackey SA; Berlin CM Clin Pediatr (Phila); 1992 Jul; 31(7):394-9. PubMed ID: 1617863 [TBL] [Abstract][Full Text] [Related]
35. The factor analytic, logarithmic and optimum solutions in separating heterozygous carriers and normal control subjects in phenylketonuria. Kääriäinen R Hereditas; 1973; 75(2):241-9. PubMed ID: 4782045 [No Abstract] [Full Text] [Related]
36. Heterozygote detection in phenylketonuria. Measurement of discriminatory ability and interpretation of the phenylalanine loading test by determination of the heterozygote likelihood ratio. Westwood A; Raine DN J Med Genet; 1975 Dec; 12(4):327-33. PubMed ID: 1219115 [TBL] [Abstract][Full Text] [Related]
37. Simultaneous measurement of phenylalanine and tyrosine in phenylketonuric plasma and dried blood by high-performance liquid chromatography. Dale Y; Mackey V; Mushi R; Nyanda A; Maleque M; Ike J J Chromatogr B Analyt Technol Biomed Life Sci; 2003 May; 788(1):1-8. PubMed ID: 12668065 [TBL] [Abstract][Full Text] [Related]
38. Gas chromatography-mass spectrometry method for determination of phenylalanine and tyrosine in neonatal blood spots. Deng C; Deng Y; Wang B; Yang X J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Nov; 780(2):407-13. PubMed ID: 12401368 [TBL] [Abstract][Full Text] [Related]
39. [Intracellular concentration of phenylalanine, tyrosine and alpha-amino butyric acid in 13 homozygotes and 19 heterozygotes for phenylketonuria (PKU) compared with 26 normals (author's transl)]. Thalhammer O; Pollak A; Lubec G; Königshofer H Klin Padiatr; 1980 Nov; 192(6):608-12. PubMed ID: 7194402 [TBL] [Abstract][Full Text] [Related]
40. [Method of detection of heterozygotic carrier state in phenylketonuria]. Baikov AD; Sitnichenko EI Lab Delo; 1973; 5():293-5. PubMed ID: 4129158 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]